Scheen, André J. http://orcid.org/0000-0001-9743-4371
Article History
Accepted: 3 July 2020
First Online: 27 August 2020
Competing interests
: A.J.S. has received lecturer, scientific advisory and clinical investigator fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Novartis, NovoNordisk, Sanofi and Servier. He worked as a clinical investigator in the EMPA-REG OUTCOME, CANVAS-R and DECLARE-TIMI 58 trials.